Podcasts about Mantle cell lymphoma

  • 119PODCASTS
  • 492EPISODES
  • 57mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Jan 15, 2025LATEST
Mantle cell lymphoma

POPULARITY

20172018201920202021202220232024


Best podcasts about Mantle cell lymphoma

Latest podcast episodes about Mantle cell lymphoma

Oncology Today with Dr Neil Love
CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

Oncology Today with Dr Neil Love

Play Episode Listen Later Jan 15, 2025 120:28


Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

Blood Cancer Talks
ASH 2024 Lymphoma and CLL Highlights

Blood Cancer Talks

Play Episode Listen Later Dec 22, 2024 58:18


In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.htmlb) ENRICT Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.htmlc) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html2. DLBCL: a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.htmlb) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.htmlc) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html3. Follicular Lymphoma: a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.htmlb) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract4. CLL: a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html5. Hodgkin Lymphoma: a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html

Marrow Masters
Terena Shares Her CAR T-Cellular Therapy Journey

Marrow Masters

Play Episode Listen Later Nov 15, 2024 28:29


(Disclaimer: This episode contains advice on nutrition and lifestyle. Always consult your health care team regarding your personal circumstances).In this episode, we speak with Terena from Tampa, Florida, about her journey with CAR T-cell therapy, covering her experiences from diagnosis through recovery and remission. Diagnosed with mantle cell lymphoma, a type of non-Hodgkin's lymphoma, in September 2019, Terena endured years of misdiagnosis as her initial symptoms, such as severe hot flashes and night sweats, were attributed to menopause. It wasn't until a bone marrow biopsy that she was correctly diagnosed.Following her diagnosis, Terena underwent extensive testing, including specialized genetic tests like FoundationOne Heme and clonoSEQ, which helped tailor her treatment plan. She started on a combination therapy of Revlimid and rituximab before transitioning to CAR T-cell therapy in December 2020. She shares how the preparation for CAR T involved rigorous health screenings, including mental health assessments and apheresis, to collect her T cells.Terena details the intensive hospital stay during CAR T, where she faced several challenging side effects like cytokine release syndrome, neurotoxicity, and significant weight loss due to radiation-induced nausea. Despite these challenges, she avoided some severe complications such as seizures or viral reactivations, thanks to preemptive treatments and vigilant care. Her remission came three months post-treatment, a milestone that was both a relief and a testament to the effectiveness of the therapy.The cost of CAR T therapy was staggering, with an itemized hospital bill exceeding a million dollars. Fortunately, her insurance (including Medicare) covered a significant portion, though she emphasizes the importance of being financially prepared for such high medical expenses.Post-remission, Terena has made significant lifestyle changes to support her health. She follows a strict anti-inflammatory diet, avoiding GMOs, processed foods, and conventional dairy and meat products. She shares her regimen of juicing, incorporating nutrient-rich foods like organic berries, avocados, and cruciferous vegetables. Additionally, she has overhauled her home environment, switching to non-toxic cleaning products and cosmetics, using water and air filters, and incorporating wellness practices like infrared sauna therapy and regular exercise.Terena's commitment to reducing environmental toxins extends to every aspect of her life. She no longer uses products with harmful chemicals, such as nail polish or hair dye, and relies on digital tools to evaluate the safety of her food and personal care products. Her integrative health approach, combining conventional and holistic practices, plays a crucial role in maintaining her well-being.Her story is not only about overcoming physical challenges but also about the emotional and logistical aspects of undergoing such intensive treatment. From pre-paying bills and preparing meals in advance to relying on friends and family for transportation during her recovery, Terena's experience highlights the need for a strong support system. Her openness and detailed sharing of her journey are bound to help others navigating similar paths.Links: Gluten Free Scanner App: https://glutenfreescanner.app/EWG's "Clean Fifteen" List: https://www.ewg.org/foodnews/clean-fifteen.phpEWG's "Dirty Dozen" List: https://www.ewg.org/foodnews/full-list.phpFoundationOne Heme - foundationmedicine.comclonoSEQ - clonoseq.comThis season is made possible thanks to our sponsors:Kite, a Gilead company: http://www.kitepharma.com/and Bristol Myers Squibb's CAR T support services program:https://www.celltherapy360.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/Or visit our website at https://www.nbmtlink.org/

Research To Practice | Oncology Videos
Mantle Cell Lymphoma | Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 30, 2024 57:58


Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics: Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00) Key Datasets — Overview and First-Line Therapy (7:16) Faculty Case Presentations — Dr Phillips (27:03) Key Datasets — Relapsed/Refractory Disease (35:40) Faculty Case Presentations — Dr Wang (48:06) CME information and select publications  

Research To Practice | Oncology Videos
Mantle Cell Lymphoma | Michael Wang, MD

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 30, 2024 53:11


Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD CME information and select publications.

Hematologic Oncology Update
Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma

Hematologic Oncology Update

Play Episode Listen Later Oct 30, 2024 57:58


Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

VJHemOnc Podcast
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events

VJHemOnc Podcast

Play Episode Listen Later Oct 30, 2024 9:30


Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will... The post Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events appeared first on VJHemOnc.

Oncology Today with Dr Neil Love
Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma

Oncology Today with Dr Neil Love

Play Episode Listen Later Oct 29, 2024 57:58


Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTKInhibitorsMCL24).

WolverHeme Happy Hour
Episode 27: Mantle Cell Masterclass with Tycel Phillips

WolverHeme Happy Hour

Play Episode Listen Later Oct 10, 2024 61:12


In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL. TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/ Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/

Cancer Buzz
Establishing Goals of Treatment in Relapsed/Refractory Mantle Cell Lymphoma

Cancer Buzz

Play Episode Listen Later Oct 1, 2024 5:35


Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population. “Fortunately, treatments such as BTK inhibitors are generally very well tolerated by patients, and there are very few patients who can't take a BTK inhibitor. But as you go up the scale of increasing intensity, such as CAR T-cell, or even allogeneic stem cell transplantation, those are therapies not suitable for patients with more extensive comorbidities.” – Dr. Jeff Sharman, MD   “A collaborative relationship between a community practice and an academic center can be of considerable benefit to a patient, so that as treatment decisions are made, both the physician and patient can feel like they're offering the patient the very best therapy.” – Dr. Jeff Sharman, MD    Jeff Sharman, MD  Medical Director of Hematology Research, US Oncology Director of Research Willamette Valley Cancer Institute Eugene, Oregon    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy The CAR T-cell Therapy Process Patient-Caregiver CAR T-cell Therapy Facts Learn About CAR T-cell Therapy Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society

Cancer Buzz
Shared Decision Making in Relapsed/Refractory Mantle Cell Lymphoma

Cancer Buzz

Play Episode Listen Later Sep 24, 2024 8:21


The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.  “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf   

ReachMD CME
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

ReachMD CME

Play Episode Listen Later Sep 24, 2024


CME credits: 1.00 Valid until: 24-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/noncovalent-btk-inhibitors-new-targeted-options-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/24362/ This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton's tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.=

Cancer Buzz
Shared Decision Making in Relapsed/Refractory Mantle Cell Lymphoma

Cancer Buzz

Play Episode Listen Later Sep 19, 2024 8:21


The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma. “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC     Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf         

Treating Blood Cancers
Unpacking Mantle Cell Lymphoma

Treating Blood Cancers

Play Episode Listen Later Sep 13, 2024 33:36


Krish Patel, MD, Swedish Cancer Institute, Seattle, WA Recorded on June 6, 2024 Krish Patel, MD Director, Lymphoma Program Director, Hematologic Malignancies and Cellular Therapy Swedish Cancer Institute Seattle, WA Join us as Dr. Krish Patel from Swedish Cancer Institute explores mantle cell lymphoma, including the goals and latest advancements in treatment. He also provides insights on treating relapsed/refractory cases, discusses effective strategies for managing side effects, and highlights the importance of communication between patients and healthcare professionals for optimal care. Tune in to stay up to date on mantle cell lymphoma today!

Blood Podcast
Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors

Blood Podcast

Play Episode Listen Later Aug 29, 2024 0:59


In this week's episode we'll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors.Featured Articles: Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD studyMass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy inmultiple myelomaIn vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

Cancer Buzz
Adverse Event Management in Relapsed/Refractory Mantle Cell Lymphoma

Cancer Buzz

Play Episode Listen Later Aug 8, 2024 6:49


Common adverse events associated with treatment of mantle cell lymphoma include gastrointestinal, hematologic, and cardiac toxicities. Proactive management of these toxicities and collaboration between members of the cancer care team, including pharmacists, are key to optimizing patient outcomes. In this episode, CANCER BUZZ speaks with Karen Fancher, PharmD, BCOP, clinical pharmacy specialist in oncology at University of Pittsburgh – Passavant Hospital, and Victoria Nachar, PharmD, BCOP, clinical pharmacist specialist in ambulatory hematology and adjunct clinical instructor at the University of Michigan, about strategies to address common adverse events experienced by patients with mantle cell lymphoma.  “There are some unique strategies using electronic resources if patients can be tech-savvy…We have some cool technology that use[s] text-message-based responses, where you can ask patients about side effects or vital signs. All they have to do is text a response, and it will automatically populate into the electronic medical record.”—Victoria Nachar, PharmD, BCOP   “I'm at a very small community practice…Institutions like Michigan are light years ahead of some of us in terms of patient-friendly communication strategies through technology…As those institutions perfect and work out the kinks, [the technology] is going to trickle down to those of us in the community setting. And I'm really excited to see how we can harness that technology for patients.”—Karen Fancher, PharmD, BCOP     Victoria Nachar, PharmD, BCOP  Clinical Pharmacist Specialist, Ambulatory Hematology  Adjunct Clinical Instructor  University of Michigan Rogel Cancer Center Ann Arbor, MI    Karen Fancher, PharmD, BCOP    Clinical Pharmacy Specialist, Oncology University of Pittsburgh Medical Center – Passavant Hospital Associate Professor of Pharmacy Practice   Duquesne University School of Pharmacy   Pittsburgh, PA    This video podcast was produced in partnership with The Leukemia & Lymphoma Society and made possible with support from Eli Lilly. Resources Cancer Diagnostics Education Program - ACCC Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy The CAR T-cell Therapy Process Patient-Caregiver CAR T-cell Therapy Facts Learn About CAR T-cell Therapy  Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society

Best of Oncology Podcast Series
EHA HIGHLIGHTS 2024 - LYMPHOMA ROUNDTABLE DISCUSSION: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

Best of Oncology Podcast Series

Play Episode Listen Later Jun 27, 2024 5:07


Research To Practice | Oncology Videos
Lymphoma | Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences

Research To Practice | Oncology Videos

Play Episode Listen Later May 29, 2024 76:46


Featuring perspectives from Dr Andrew D Zelenetz, including the following topics: Follicular Lymphoma (0:00) Mantle Cell Lymphoma (30:29) Diffuse Large B-Cell Lymphoma (55:01) Hodgkin Lymphoma (1:12:25) CME information and select publications

Oncology Today with Dr Neil Love
Key Presentations on Lymphoma from Recent Major Conferences

Oncology Today with Dr Neil Love

Play Episode Listen Later May 28, 2024 76:45


Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostConf24/Lymphoma).

Research To Practice | Oncology Videos
Lymphoma | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 27, 2024 60:14


Featuring perspectives from Dr Andrew M Evens and Dr Sonali M Smith, including the following topics:  Introduction: CD3-Based Bispecific Antibodies and the General Medical Oncologist: Lymphomas, Multiple Myeloma … and Solid Tumors? (0:00) Follicular and Mantle Cell Lymphoma (7:17) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (30:10) CME information and select publications   

Oncology Times - OT Broadcasts from the iPad Archives
Important Mantle Cell Lymphoma Findings From the Sympatico Study

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Mar 12, 2024 13:55


How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center in Houston, told the conference how a combination of two targeted drugs—ibrutinib and venetoclax—improved outcomes.

Oncology Peer Review On-The-Go
S1 Ep95: Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management

Oncology Peer Review On-The-Go

Play Episode Listen Later Feb 5, 2024 11:25


Although strides have been made with Bruton tyrosine kinase (BTK) inhibitors and CAR-T cell therapy, relapse and resistance remain significant hurdles in treating patients with mantle cell lymphoma (MCL). The Lymphoma Research Foundation's 2023 MCL Scientific Consortium and Workshop addressed these complexities, aiming to dissect the intricate biology of MCL and propel progress towards a cure. CancerNetwork® spoke with leaders in the MCL field to better understand the aim of the consortium and the advancements they hope to see in the space. The journal ONCOLOGY® published these findings in the February 2024 issue. The interviews included Elias Campo, MD, PhD, research director and professor of anatomic pathology at the Hospital Clinic of the University of Barcelona; Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas, MD Anderson Cancer Center; Martin Dreyling, MD, PhD, professor of Medicine in the Department of Medicine and head of the Medical Clinic 3 at the University of Munich-Grosshadern in Germany; and Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor and division chief in the Division of Hematology at the University of Nebraska Medical Center and coeditor in chief of ONCOLOGY.  The consortium touched on t(11;14), which dysregulates cyclin D1 and fuels uncontrolled cell growth. Additionally, research presented at the consortium revealed other molecular pathways contributing to treatment resistance and relapse, highlighting the heterogeneous nature of the disease. This heterogeneity underscored the need for personalized treatment strategies and biomarker-based prognostics, a notion further emphasized by multiple findings on the predictive value of specific gene mutations. Beyond understanding the inner workings of MCL, presentations also focused on novel therapeutic avenues. Specifically, there were encouraging data on the potential of next-generation BTK inhibitors including acalabrutinib (Calquence) to overcome resistance. Challenges such as the limitations of current risk stratification models remain, underscoring the need for robust biomarkers to guide early interventions and optimize treatment selection. Additionally, the consortium featured a discussion on addressing a lack of diversity in clinical trial populations, which may help increase treatment access for those with various medical conditions. “…The patient population that has a disease is not always [represented] in the clinical trials. That's why it's important to be able to have a diversity of patients in clinical trials: to test these new therapies because [patients] may have other medical conditions that would change the outcome of trials and not be necessarily representative of the entire patient population with that disease,” Vose said. “It's important to try to advance the treatment of a very diverse patient population through these clinical trial mechanisms.”

Two Onc Docs
Mantle Cell Lymphoma

Two Onc Docs

Play Episode Listen Later Jan 29, 2024 9:41


This week's episode will be focusing on Mantle Cell Lymphoma. We will go over the important details on the presentation, diagnosis and treatment.

Oncology Data Advisor
Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD

Oncology Data Advisor

Play Episode Listen Later Jan 2, 2024 6:12


At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!

Oncology Data Advisor
Expanding Access to Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Andre Goy, MD

Oncology Data Advisor

Play Episode Listen Later Dec 21, 2023 10:47


At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!

Blood Cancer Talks
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre

Blood Cancer Talks

Play Episode Listen Later Dec 20, 2023 50:59


In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180069.html 2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)  https://ash.confex.com/ash/2023/webprogram/Paper191921.html Chronic Lymphocytic Leukemia 1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063 2. Ibrutinib retreatment in Phase 2 CAPTIVATE study: https://ash.confex.com/ash/2023/webprogram/Paper187128.html Hodgkin Lymphoma 1. S1826 outcomes in older adults:  https://ash.confex.com/ash/2023/webprogram/Paper180114.html Diffuse Large B-cell Lymphoma 1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180381.html 2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper177588.html

Blood Cancer Talks
Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson

Blood Cancer Talks

Play Episode Listen Later Nov 30, 2023 68:40


In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/31451445/ 3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36548927/ 4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:https://pubmed.ncbi.nlm.nih.gov/35803286/ 5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/35366963/ 6. Epcoritamab + R2 in high-risk follicular lymphoma:https://meetings.asco.org/abstracts-presentations/218265 7. Glofitamab in Mantle Cell Lymphoma:https://ashpublications.org/blood/article/140/Supplement%201/178/489039

CCO Oncology Podcast
A Year in Review and a Look to the Future: BTKi in CLL and MCL

CCO Oncology Podcast

Play Episode Listen Later Nov 20, 2023 27:33


In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL ZUMA-2: Brexucabtagene Autoleucel in R/R MCL BRUIN: Pirtobrutinib for Previously Treated MCL GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL BRUIN: Pirtobrutinib for Previously Treated CLLPresenters: Ana Marin-Niebla, MD, PhDHematology Consultant, Lymphoma UnitVall d'Hebron Institute of Oncology, Hematology DepartmentHospital Universitario Vall d'HebronBarcelona, SpainStephan Stilgenbauer, MDMedical Director Comprehensive Cancer Center UlmHead, Early Clinical Trials UnitHead, Division of CLL Dept. of Internal Medicine IIIUniversity Medical CenterUlm UniversityUlm, GermanyLink to full program: https://bit.ly/3MNaUri

VJHemOnc Podcast
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma

VJHemOnc Podcast

Play Episode Listen Later Nov 3, 2023 14:38


The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as... The post iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma appeared first on VJHemOnc.

Blood Podcast
Lenalinomide plus rituximab for elderly patients with DLBCL, platelet GP6-mediated neutrophil recruitment in acute lung injury, and the role of AXL3 in mantle cell lymphoma.

Blood Podcast

Play Episode Listen Later Oct 26, 2023 19:25


In this week's episode, we discuss the findings from a phase 2 study of lenalinomide plus rituximab in elderly frail patients with DLBCL, learn more about platelet GP6-mediated neutrophil recruitment in early stages of acute lung injury, and discuss a newly identified isoform of the tyrosine kinase AXL, termed AXL3, in mantle cell lymphoma.

Research To Practice | Oncology Videos
Mantle Cell Lymphoma | What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 19, 2023 61:34


Featuring perspectives from Dr Toby A Eyre and Dr Brad S Kahl, including the following topics: Introduction: Mantle Cell Lymphoma (MCL) and the General Medical Oncologist (0:00) Sequencing of Therapy for MCL: 2009-2025 (11:19) Cases and Questions from the Community (36:44) Case: A man in his early 80s with relapsed/refractory MCL with “brain fog” on zanubrutinib — Zanetta S Lamar, MD (56:07) CME information and select publications

Hematologic Oncology Update
What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

Hematologic Oncology Update

Play Episode Listen Later Oct 19, 2023 61:33


Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.

Oncology Today with Dr Neil Love
What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

Oncology Today with Dr Neil Love

Play Episode Listen Later Oct 18, 2023 61:25


Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma. CME information and select publications here (https://www.researchtopractice.com/RRMCL2023)

Research To Practice | Oncology Videos
Mantle Cell Lymphoma | Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 31, 2023 21:28


Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics: Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00) Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36) Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14) Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16) Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23) CME information and select publications

Research To Practice | Oncology Videos
Mantle Cell Lymphoma | Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 31, 2023 42:19


Featuring perspectives from Dr Michael Wang, including the following topics: Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00) First- and second-line therapy approaches for MCL (7:26) Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21) Current role of ibrutinib in the treatment of MCL; use of single-agent venetoclax and of zanubrutinib in the treatment algorithm (14:59) Case: A 68-year-old man presenting with an enlarged spleen, no lymphadenopathy and a white blood cell count of 300,000 is diagnosed with MCL (17:48) Case: A 71-year-old man with multiregimen-relapsed, nodular type MCL presents with lymphadenopathy and a 3-cm tumor near the mediastinum (22:38) Patient selection for chimeric antigen receptor T-cell therapy (25:59) Novel and investigational therapeutic approaches for MCL (30:11) Treatment approaches for other histological variants of MCL (39:00) CME information and select publications

Hematologic Oncology Update
Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma

Hematologic Oncology Update

Play Episode Listen Later Aug 31, 2023 42:33


Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

Oncology Today with Dr Neil Love
Role of BTK Inhibitors in Therapy for Mantle Cell Lymphoma

Oncology Today with Dr Neil Love

Play Episode Listen Later Aug 30, 2023 42:27


Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love. CME information and select publications here (https://researchtopractice.com/OncologyTodayBTKInhibitorsMCL23).

Oncology Today with Dr Neil Love
Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin Lymphoma

Oncology Today with Dr Neil Love

Play Episode Listen Later Jul 6, 2023 61:14


Medscape InDiscussion: CAR T-Cell Therapy
Monitoring and Management of CAR T-Cell Therapy Complications

Medscape InDiscussion: CAR T-Cell Therapy

Play Episode Listen Later May 11, 2023 21:34


Join Drs Amelia Langston and Jean Koff as they discuss the monitoring and management of complications before, during, and after CAR T therapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987066). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/ On-target and Off-target-based Toxicologic Effects https://pubmed.ncbi.nlm.nih.gov/23085982/ Cytokine https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cytokine Tocilizumab (Rx) https://reference.medscape.com/drug/actemra-tocilizumab-999419 CARTOX 10 Point Neurological Assessment https://reference.medscape.com/viewarticle/886616_5 Levetiracetam https://www.ncbi.nlm.nih.gov/books/NBK499890/ Cytopenia After CAR-T Cell Therapy-A Brief Review of a Complex Problem https://pubmed.ncbi.nlm.nih.gov/35326654/ Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome https://pubmed.ncbi.nlm.nih.gov/36906275/ Management of Hypogammaglobulinaemia and B-cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/ Rituximab (Rx) https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243 Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-cell Products in B-cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/ Mantle Cell Lymphoma https://www.ncbi.nlm.nih.gov/books/NBK536985/ Chimeric Antigen Receptor (CAR) T-cell Treatment for Mantle Cell Lymphoma (MCL) https://pubmed.ncbi.nlm.nih.gov/35237395/ Apheresis https://www.cancer.gov/publications/dictionaries/cancer-terms/def/apheresis

Blood Cancer Talks
Episode 21. Newly Diagnosed Mantle Cell Lymphoma

Blood Cancer Talks

Play Episode Listen Later May 3, 2023 46:05


In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes:2:11 How to diagnose mantle cell lymphoma (MCL)?6:51 Clinical manifestations of mantle cell lymphoma7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67?17:21 Overview on treatment of newly diagnosed MCL19:03 Are all cytarabine-based regimens for MCL created equally?  RCT of Autologous Transplantation in MCL: https://pubmed.ncbi.nlm.nih.gov/15591112/21:39 In a world without upfront ibrutinib access as per TRIANGLE trial, do all fit patients with MCL need consolidation with auto-transplant? 22:44 How to approach unfit patients with newly diagnosed MCL? RCT of bortezomib-based therapy (VR-CAP) in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/25738670/24:57 SHINE Trial-RCT of Ibrutinib plus BR in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/35657079/30:38 TRIANGLE Trial-RCT of upfront ibrutinib with or without auto-transplant in newly diagnosed MCL:https://ashpublications.org/blood/article/134/Supplement_1/2816/42350443:01: Does Allo-Transplant have any role in MCL?44:08: What are the likely next breakthroughs in newly diagnosed MCL space? 

Gorge Real Estate Talk
EP 49 - Keeping Kim's vision alive

Gorge Real Estate Talk

Play Episode Listen Later Apr 28, 2023 38:35


After taking some time for reflection and healing, we are thrilled to announce the continuation of Gorge Real Estate Talk. As many of you are aware, our beloved host and dear friend, Kimberly Salvesen, passed away on January 1st, 2023 after a courageous battle with Mantle Cell Lymphoma. Despite her diagnosis, Kim's indomitable spirit fueled her passion for the podcast and the real estate market. Initially created to keep our community members informed about the current state of the real estate market, the podcast evolved into a platform to spotlight local businesses and community programs. In today's episode, our new host, Alisha Nightingale, chats with Rachel Broughton and Kim Chamness, the new owners of Windermere Real Estate Columbia River Gorge, about Kim's remarkable legacy and the seamless transition of ownership. Although Kim's loss remains a heavy burden on our hearts and minds, the Windermere family has come together in a beautiful way to keep her vision alive. During this episode, you will hear from some of Kim's closest friends and colleagues about her inspiring impact as a mentor, a friend, and a pioneer in the real estate industry. We hope this special episode will serve as a touching tribute to Kim Salvesen and her extraordinary life. Moving forward, we have lined up some incredible guests and exciting topics that we can't wait to share with you. We appreciate your unwavering support and look forward to continuing this journey together.   To learn more about Kim Salvesen and her incredible life's journey, please visit below.   https://www.columbiagorgenews.com/obituaries/obituary-kimberly-salvesen/article_ff07bc60-92be-11ed-b330-7b96ff7e530f.html

PeerVoice Oncology & Haematology Video
Laurie H. Sehn, MD, MPH - Clinical Update in the Treatment of Mantle Cell Lymphoma: The Evolving Evidence of BTK Inhibitors

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Apr 27, 2023 10:39


Laurie H. Sehn, MD, MPH - Clinical Update in the Treatment of Mantle Cell Lymphoma: The Evolving Evidence of BTK Inhibitors

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
FDA D.I.S.C.O. Burst Edition: FDA approvals of Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma, and Orserdu (elacestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Play Episode Listen Later Mar 1, 2023 6:59


Listen to a soundcast of the January 27, 2023, FDA approvals of Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma, and Orserdu (elacestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Research To Practice | Oncology Videos
Hodgkin and Non-Hodgkin Lymphomas | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas

Research To Practice | Oncology Videos

Play Episode Listen Later Feb 18, 2023 63:44


Featuring perspectives from Drs Christopher Flowers and Laurie Sehn, including the following topics: •      Introduction (0:00) •      Treatment for Diffuse Large B-Cell Lymphoma (7:45) •      Management of Hodgkin Lymphoma (35:33) •      Follicular Lymphoma (41:57) •      Caring for Patients with Mantle Cell Lymphoma (51:38) CME information and select publications

Blood Cancer Talks
Episode 11. ASH22 Recap: Lymphoma and CLL

Blood Cancer Talks

Play Episode Listen Later Dec 21, 2022 39:02


ALPINE Trial: Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL (https://www.nejm.org/doi/full/10.1056/NEJMoa2211582) CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (https://ash.confex.com/ash/2022/webprogram/Paper163245.html)  AVO Trial: Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease (https://ash.confex.com/ash/2022/webprogram/Paper168003.html)  Watch-and-Wait RCT in Follicular Lymphoma: Long-term follow-up of Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma (https://ash.confex.com/ash/2022/webprogram/Paper156790.html) Augment Trial: Update of Phase 3 RCT comparing Rituximab-Revlimid (R2) vs Rituximab-Placebo in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (https://ash.confex.com/ash/2022/webprogram/Paper158631.html) TRIANGLE Study: Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma (https://ash.confex.com/ash/2022/webprogram/Paper163018.html) 

Research To Practice | Oncology Videos
Chronic Lymphocytic Leukemia and Lymphomas | Proceedings from a Daylong Multitumor Educational Symposium in Partnership with Florida Cancer Specialists

Research To Practice | Oncology Videos

Play Episode Listen Later Nov 16, 2022 61:06


Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Ann LaCasce and Mitchell Smith, including the following topics: Hodgkin Lymphoma and CLL (0:00) Bispecific Antibodies, CAR T-Cell Therapy; Diffuse Large B-Cell Lymphoma (32:31) Treatment for Mantle Cell Lymphoma (53:23) CME information and select publications

Blood Podcast
Lineage switching in MLL/AF4 leukemia, ibrutinib in mantle cell lymphoma with CNS relapse, and gilteritinib plus azacitidine in newly diagnosed FLT3-mutated AML

Blood Podcast

Play Episode Listen Later Oct 27, 2022 22:58


In this week's episode we'll discuss the role of epigenetic regulator genes in lineage switching in MLL/AF4 leukemia, learn more about the efficacy of ibrutinib in mantle cell lymphoma with central nervous system relapse, and discuss the findings from a phase 3 trial of gilteritinib plus azacitidine in patients with newly diagnosed FLT3-mutated AML.

The Bloodline with LLS
Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy

The Bloodline with LLS

Play Episode Listen Later May 23, 2022 34:27


Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of… The post Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy first appeared on The Bloodline with LLS.

The Bloodline with LLS
Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy

The Bloodline with LLS

Play Episode Listen Later May 23, 2022 34:27


Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of… The post Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy appeared first on The Bloodline with LLS.

A Quest for Well-Being
The Gifts Of Cancer, Spirituality & The Miracle Of Life

A Quest for Well-Being

Play Episode Listen Later May 11, 2022 45:36


— As a happily married, fifty-five-year-old professional woman, Susan Keller had it all—or thought she did—until the day of her shocking diagnosis with stage 4 Mantle Cell Lymphoma, a rare and aggressive disease. Within minutes of being admitted to the hospital, her beautifully ordinary life disappeared. How would cancer affect her marriage? Facing a possible death sentence, Susan experienced visions so lucid and beautiful that she imagined she was looking into the foyer of death or a magnificent afterlife. Her mind and body melded into all that surrounded her. Bliss replaced fear. Cancer and spirituality were one. But during the darkest moments, Susan questioned the nature of mortality. Does death have the same shape, sound, and feeling for everyone? Did the father she yearned for think of her the moment he died? What would she think of? Would there be regret, celebration, or nothingness? After months of grueling inpatient chemo, she faced another seemingly impossible hurdle. To survive, she needed a bone marrow transplant. But Johnny—her brilliant, off-the-grid brother—was the only possible donor. But he'd vanished decades earlier. Blood Brother is a family saga of curing an incurable cancer and of the enigmatic events that led to finding a man who never wanted to be found. It also explores why he disappeared and delves into what it means to forgive the parents who abused and abandoned them. Susan survived twice: once a violent childhood and secondly a devastating cancer. Blood Brother is a story of life after a bone marrow transplant. It's a moving tale of rebuilding a family, recognizing the unexpectedly stunning gifts of cancer, and of how to embrace a profoundly generous second chance at life. Valeria Teles interviews Susan Keller — The author of “Blood Brother: A Memoir.” Susan Keller enjoyed a 30-year career as an award-winning medical writer. Her poetry won prizes in regional and national contests. She has a degree in Public Health and Immunology from U. C. Berkeley.  This background in science as well as poetry makes the voice in her first book, Blood Brother: A Memoir, both lyric as well as credible.  A frequently fatal lymphoma inspired Susan to write Blood Brother: A Memoir. Articles about her story of hope and survival have been published in: Psychology Today; Conquer: The Patient Voice; two Guideposts Magazines; Patient Power; and several newspapers. She is a monthly blog contributor to Psychology Today and CURE Magazine. Susan is a presenter at Dominican University and at Stanford Cancer Center. All links available upon request. She is currently working on a novel entitled Flask. Susan lives in the Bay Area with her husband, Daniel.  To learn more about Susan Keller and her work, please visit: susankeller.com   — This podcast is a quest for well-being, a quest for a meaningful life through the exploration of fundamental truths, enlightening ideas, insights on physical, mental, and spiritual health. The inspiration is Love. The aspiration is to awaken new ways of thinking that can lead us to a new way of being, being well.